Table 3.
Sample size calculation using native ShMOLLI T1-mapping for clinical studies and trials, arranged according to Cohen’s d effect size (largest to smallest)
| Departure of focally abnormal myocardium from reference myocardium (within subjects) | Departure of reference myocardium from healthy myocardium [19] (between groups) | |||
|---|---|---|---|---|
| Cohen-d | Paired, n> | Cohen-d | Unpaired, n> | |
| Patients with normal CMR | N/A | N/A | 0.14 | 1604 |
| Cardiac Amyloidosis (AL) | 4.58 | 2 | – | – |
| Cardiac Amyloidosis (ATTR) | 3.91 | 4 | 1.28 | 9 |
| Aortic Stenosis | 3.39 | 6 | 0.68 | 146 |
| Takotsubo Cardiomyopathy | 3.33 | 6 | 1.06 | 32 |
| Dilated Cardiomyopathy | 3.09 | 6 | 0.56 | 104 |
| Pheochromocytoma | 3.02 | 6 | 0.09 | 3880 |
| Myocarditis (acute) | 2.92 | 6 | 0.52 | 120 |
| Obesity | 2.81 | 8 | 0.21 | 716 |
| Hypertension | 2.36 | 8 | 0.57 | 100 |
| Myocarditis(previous) | 2.30 | 10 | 0.0 | N/A |
| Cardiac Sarcoidosis | 2.28 | 10 | 0.0 | N/A |
| Cardiac Iron-Overloada | 2.06 | 10 | 13.30 | 4 |
| Chronic CAD | 2.06 | 10 | 0.47 | 146 |
| Hypertrophic Cardiomyopathy | 1.59 | 16 | 0.15 | 1398 |
| Atrial Fibrillationa | 1.47 | 18 | 0.29 | 376 |
| Anderson-Fabry Diseasea | 0.82 | 50 | 2.81 | 8 |
All abbreviations are as per Tables 1 and 2. Focally abnormal myocardium: myocardium affected by either late gadolinium enhancement (LGE) or by regional wall motion abnormalities (RWMA) defined as severe hypokinesia, akinesia or dyskinesia on cines in patients with Takotsubo cardiomyopathy. Reference myocardium: myocardium not affected by RMWA or LGE. aindicates material from extended analysis period included to address peer review